NRBO insider filings
NeuroBo Pharmaceuticals, Inc. — 34 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-09-20. Screen NRBO transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for NRBO between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — NeuroBo Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-09-20 | 4 | DONG-A ST CO., LTD — 10% owner | Sale (S): 407 @ $3.75 · Purchase (P): 2,544,530 (derivative) · Purchase (P): 3,816,795 (derivative) | EDGAR |
| 2024-08-13 | 4 | Kim Hyung Heon — CEO & President, Director | Tax withholding (F): 11,467 @ $3.60 | EDGAR |
| 2024-07-10 | 4/A | DONG-A ST CO., LTD — 10% owner | Purchase (P): 2,544,530 @ $3.93 | EDGAR |
| 2024-06-25 | 4 | DONG-A ST CO., LTD — 10% owner | Purchase (P): 2,544,530 @ $3.13 | EDGAR |
| 2024-06-07 | 4 | Salsbury Michael — Director | Grant/award (A): 5,051 @ $0 | EDGAR |
| 2024-06-07 | 4 | Tursi James Patrick — Director | Grant/award (A): 5,051 @ $0 | EDGAR |
| 2024-06-07 | 4 | GROVES JASON L — Director | Grant/award (A): 5,051 @ $0 | EDGAR |
| 2024-06-07 | 4 | Glickman Mark A — Director | Grant/award (A): 5,051 @ $0 | EDGAR |
| 2024-06-07 | 4 | KOVEN ANDREW I — Director | Grant/award (A): 5,051 @ $0 | EDGAR |
| 2024-06-07 | 4 | STRICKLAND D GORDON — Director | Grant/award (A): 5,051 @ $0 | EDGAR |
| 2024-03-04 | 4 | Woodworth Marshall H — Chief Financial Officer | Grant/award (A): 33,496 @ $0 | EDGAR |
| 2023-12-04 | 4 | Tursi James Patrick — Director | Grant/award (A): 25,000 @ $0 · Grant/award (A): 7,157 @ $0 | EDGAR |
| 2023-08-14 | 4 | Kim Hyung Heon — CEO & President, Director | Grant/award (A): 625,064 @ $0 | EDGAR |
| 2023-07-28 | 4 | Salsbury Michael — Director | Grant/award (A): 87,500 @ $0 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2023-07-28 | 4 | Kim Na Yeon — Director, 10% owner | Grant/award (A): 87,500 @ $0 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2023-07-28 | 4/A | Kim Na Yeon — Director, 10% owner | Other (J): 4,671 @ $0 | EDGAR |
| 2023-07-28 | 4 | GROVES JASON L — Director | Grant/award (A): 87,500 @ $0 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2023-07-28 | 4 | Glickman Mark A — Director | Grant/award (A): 25,000 @ $0 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2023-07-28 | 4 | KOVEN ANDREW I — Director | Grant/award (A): 87,500 @ $0 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2023-07-28 | 4 | STRICKLAND D GORDON — Director | Grant/award (A): 87,500 @ $0 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2022-07-28 | 4 | E&Investment, Inc. — 10% owner E&Healthcare Investment Fund II — 10% owner | Other (J): 1,445,267 @ $0 | EDGAR |
| 2022-07-28 | 4 | Kim Na Yeon — Director, 10% owner | Other (J): 1,445,267 @ $0 | EDGAR |
| 2022-06-13 | 4 | Kim Na Yeon — Director, 10% owner | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | GROVES JASON L — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Kim Hyung Heon — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Kang Richard — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Salsbury Michael — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | KOVEN ANDREW I — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | STRICKLAND D GORDON — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | STRICKLAND D GORDON — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-11-04 | 4 | Price Ben Gil — CEO and President | Grant/award (A): 616,666 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4 | KOVEN ANDREW I — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Bakshi Akash — SVP and COO, Director | Grant/award (A): 29,013 · Grant/award (A): 855,059 | EDGAR |
| 2020-09-03 | 4 | Swirsky Douglas J — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — NeuroBo Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-11-17 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-16 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-05 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-28 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NRBO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs